Sign Out
Pregnancy: Ropinirole has been shown to have developmental and teratogenic effects in animals. There are no adequate or well-controlled studies in pregnant women. Ropinirole concentrations may also gradually increase during pregnancy. Thus, ropinirole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Patients should also notify their physicians if they become pregnant or intent to become pregnant during ropinirole therapy.
Lactation: There are no data regarding the excretion of ropinirole in human milk. Suppression of lactation is anticipated because ropinirole inhibits prolactin secretion in humans. Since the infant may be exposed to dopamine agonist activity, ropinirole should not be used by breastfeeding patients.
Continue with Google